Business Context and Reporting Period
This summary covers the Form 10-Q filed by PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.) for the quarterly period ended September 28, 2008. The company operates in two primary segments: Life and Analytical Sciences and Optoelectronics. The report includes unaudited condensed consolidated financial statements and management's discussion and analysis.
Key Financial Metrics
| Metric | Three Months Ended Sep 28, 2008 | Nine Months Ended Sep 28, 2008 |
|---|---|---|
| Sales | $505.1 million | $1,516.1 million |
| Operating Income (Continuing Ops) | $45.3 million | $128.7 million |
| Net Income | $51.9 million | $95.7 million |
| Diluted EPS | $0.43 | $0.80 |
| Gross Margin | 41.8% | 41.4% |
| Cash and Cash Equivalents | $188.8 million (Sep 28, 2008) | N/A |
| Long-Term Debt | $544.1 million (Sep 28, 2008) | N/A |
| Operating Cash Flow | N/A | $130.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16% ($69.4 million) for the quarter and 19% ($240.2 million) for the nine-month period compared to the prior year. Growth was driven by acquisitions (approx. 5% contribution) and favorable foreign exchange rates (approx. 2-4% contribution).
- Segment Performance:
- Life and Analytical Sciences: Sales rose 17% ($54.1 million) in the quarter, driven by genetic screening, bio-discovery, and laboratory services.
- Optoelectronics: Sales rose 13% ($15.4 million) in the quarter, led by specialty lighting and medical imaging products.
- Profitability: Operating income from continuing operations remained relatively flat for the quarter ($45.3 million vs. $45.8 million prior year) but increased 10% for the nine-month period ($128.7 million vs. $117.1 million). Gross margins improved by 83 basis points in the quarter and 138 basis points for the nine months.
- Restructuring: The company recorded $7.2 million in restructuring and lease charges for the quarter, primarily due to a Q3 2008 plan to shift resources to growth areas. This compares to a reversal of $1.4 million in the prior year quarter.
- Discontinued Operations: The company recorded a net gain of $8.1 million on the disposition of discontinued operations in the quarter, largely due to a tax benefit of $8.5 million from the settlement of income tax audits. This contrasts with a loss of $0.4 million in the prior year quarter.
Guidance, Outlook, and Risks
- Acquisitions: The company completed several acquisitions in 2008, including VaConics Lighting, LabMetrix Technologies, and the newborn metabolic screening business from Pediatrix. The ViaCell acquisition (Nov 2007) integration is ongoing, with certain non-strategic businesses (ViaCyte and Cellular Therapy Technology) classified as discontinued operations.
- Liquidity and Capital Resources: As of September 28, 2008, the company held $188.8 million in cash and had $242.0 million available under its amended senior unsecured revolving credit facility. In May 2008, the company issued $150 million in 6% senior unsecured notes due in 2015.
- Stock Repurchases: The company completed its previous 10 million share repurchase program in Q3 2008. On October 23, 2008, the Board authorized a new program to repurchase up to 10 million additional shares.
- Risks and Contingencies:
- Legal Proceedings: Ongoing litigation includes patent disputes with Enzo Biochem and PharmaStem Therapeutics. The company recently secured favorable rulings regarding PharmaStem patents, with the U.S. PTO cancelling claims in September 2008.
- Lease Guarantees: The company remains responsible for a lease guarantee related to a business sold in 2001. The buyer filed for bankruptcy in October 2008, and the company has an accrual of $2.3 million for remaining obligations.
- Market Conditions: Management notes that global financial market distress could impact credit availability, interest rates, and customer demand, though operations have not been materially affected to date.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the sustainability of the $8.1 million gain from discontinued operations, which was heavily influenced by a one-time tax benefit from audit settlements.
- Restructuring Costs: Monitor the execution of the Q3 2008 restructuring plan and the timing of remaining payments ($6.7 million accrued).
- Acquisition Integration: Assess the financial contribution of recent acquisitions (ViaCell, PKI Genetics, LabMetrix, VaConics) against integration costs and goodwill amortization.
- Lease Guarantee Exposure: Track the status of the buyer's bankruptcy and the potential for additional costs related to the 2001 lease guarantee.
- Debt Covenants: Confirm continued compliance with debt-to-capital ratios in the revolving credit facility and senior notes, especially given the increased debt load from the 2008 note issuance.